Stephen Liu

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Takeda
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Turning Point Therapeutics
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Abbvie
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Alkermes
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Elevation Oncology
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Ellipses
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Genentech
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Gilead
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merus
    Date added:
    08/14/2023
    Date updated:
    08/14/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond